# ARC-10 (NCT04736173)

> Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

No report yet. It can be ordered.

- Indication: front-line PD-L1-high locally advanced or metastatic NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04736173
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer
- Interventions: Domvanalimab; Zimberelimab; Carboplatin; Paclitaxel; Pemetrexed; Pembrolizumab
- Enrollment: 169
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on ARC-10 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=arc-10-nct04736173

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04736173", "email": "<work email>"}; the inbox owner confirms by the emailed link.